ELU001 in Pediatric Subjects Who Have Relapsed and/or Refractory CBFA2T3-GLIS2-positive AML

NCT ID: NCT05622591

Last Updated: 2024-08-07

Basic Information

• Recruitment Status: WITHDRAWN
• Clinical Phase: PHASE1
• Study Classification: INTERVENTIONAL
• Study Start Date: 2024-06-07
• Study Completion Date: 2024-06-07

Brief Summary

This research study was planned to focus on a rare type of acute myeloid leukemia (with the subtype CBFA2T3::GLIS2 that overexpresses folate receptor alpha (FRα) (a protein on the surface of leukemia cells)) that has relapsed or is refractory. Relapse means the cancer has come back after treatment. Refractory means the cancer does not respond to treatment.

Detailed Description

This study was planned as a Dose Escalation Safety Study to identify the maximum tolerated dose (MTD) and/or the recommended phase 2 dose (RP2D). This study will also evaluate the tolerability of ELU001.

ELU001 is not a drug approved by the FDA (Food and Drug Administration) yet.

Conditions

Acute Myeloid Leukemia; AML, Childhood; Relapsed Pediatric AML; Refractory Pediatric AML

Study Design

• Allocation Method: NA
• Intervention Model: SINGLE_GROUP
• Primary Study Purpose: TREATMENT
• Blinding Strategy: NONE

Study Groups

ELU001

Dose Escalation: Escalating doses of ELU001

Group Type: EXPERIMENTAL

ELU001

Intervention Type: DRUG

Folic-acid functionalized C'Dot-Drug-Conjugate (FA-CDC)

Interventions

ELU001

Folic-acid functionalized C'Dot-Drug-Conjugate (FA-CDC)

Intervention Type: DRUG

Eligibility Criteria

Inclusion Criteria

Patients must meet the following criteria to enroll in this study:

• Infants (>1 month) and children (≤9 years) at time of enrollment.
• Relapsed or refractory CBFA2T3::GLIS2 positive AML
• CNS1 or CNS2 during screening
• Performance Status: Lansky ≥ 50
• Adequate Organ Function including liver, kidney, and heart

Exclusion Criteria

Patients who meet any of the following are not eligible to enroll in this study:

• CNS3 Disease
• AML associated with congenital syndromes such as Down syndrome, Fanconi anemia, Bloom syndrome, Kostmann syndrome or Diamond-Blackfan anemia, or bone marrow failure associated with inherited syndromes.
• Acute promyelocytic leukemia.
• Clinically significant active or chronic corneal disorder, particularly corneal epitheliopathy or any eye disorder that may predispose patient to this condition, or unable to comply with an age-appropriate ophthalmologic examination.
• Prior treatment with folate receptor-targeting anti-cancer agent(s) ≤ 21 days (or 2 half-lives must have elapsed before enrollment, whichever is longer), or received investigational anti-cancer treatment ≤ 4 weeks, or within a time interval less than at least 5 half-lives of the investigational agent, prior to starting study drug, whichever is shorter.

• Minimum Eligible Age: 1 Month
• Maximum Eligible Age: 9 Years
• Eligible Sex: ALL
• Accepts Healthy Volunteers: No

Sponsors

Elucida Oncology

INDUSTRY

Sponsor Role: lead

Responsible Party

Responsibility Role: SPONSOR

Other Identifiers

ELU-FRα-AML-1

Identifier Type: -

Identifier Source: org_study_id